Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Pathog Glob Health ; 113(8): 359-363, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31910738

RESUMEN

The extension of Plasmodium falciparum resistance to existing antimalarial drugs is worrying. Faced with this problem, the search for new and effective molecules is necessary. In this context, six chalcone derivatives (B1, B11, B14, B17, SCA02 and SCA03) were tested on field isolates and then reference strains to evaluate their antiplasmodial activity by using the Rieckmann semi-microtest, recommended by WHO, for in vitro and ex vivo activity tests. Compounds B14 and B17 exhibited promising antiplasmodial activities (IC50s: 14.41-16.40 µM) regardless of the type of isolate. Compounds B1, B11, SCA02 and SCA03 showed a moderate inhibition of field isolates (IC50S: 25.63-48.29 µM) and very good activity against reference strains (IC50s: 3.82-10.03 µM). Therefore, more structural modulations should improve their efficiency and make these molecules very good candidates for future effective antimalarial drugs.


Asunto(s)
Chalcona/análogos & derivados , Chalcona/farmacología , Plasmodium falciparum/efectos de los fármacos , Animales , Antimaláricos/química , Antimaláricos/farmacología , Chalcona/química , Concentración 50 Inhibidora
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...